Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Holding AMGN?
Track your performance easily
See the Price Targets and Ratings of:
AMGN Analyst Ratings
Moderate Buy
11 Buy
10 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AMGN Stock 12 Month Forecast
Average Price Target
$333.78
▲(26.73% Upside)
| Highest Price Target$405.00 | Average Price Target$333.78 | Lowest Price Target$215.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
Reiterated
12/19/24
Oppenheimer
Reiterated
12/11/24
Bank of America Securities
Initiated
12/10/24
TD Cowen
Reiterated
12/02/24
Evercore ISI
Assigned
12/02/24
Leerink Partners
Reiterated
11/27/24
RBC Capital
Assigned
11/27/24
Truist Financial
Reiterated
11/27/24
Goldman Sachs
Reiterated
11/26/24
Morgan Stanley
Reiterated
11/26/24
BMO Capital
$362
Buy
37.44%
Upside
Reiterated
11/26/24
Evan Seigerman Recommends Buy on Amgen Due to Promising MariTide Trial Results and Strategic Growth Moves
Wells Fargo
$335
Hold
27.19%
Upside
Reiterated
11/26/24
Amgen's Stock Outlook: Balancing Maritide's Weight Loss Data Concerns and Diabetes Treatment Potential
Piper Sandler
$344
Buy
30.61%
Upside
Reiterated
11/26/24
Piper Sandler reiterates Overweight Rating on Amgen (AMGN)Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $344.00 price target on Amgen (NASDAQ: AMGN).
Deutsche Bank
$305
Hold
15.80%
Upside
Reiterated
11/26/24
Amgen (NASDAQ:AMGN) Sinks despite Positive MariTide Trial Data - TipRanks.comDespite the encouraging data, Amgen shares plunged in trading as Wall Street had anticipated weight loss outcomes closer to 25%. Deutsche Bank analyst James Shin even described the results as underwhelming, citing a 20% weight loss in Cohort A and 17% in Cohort B at 52 weeks. He also noted that its unclear if these figures are placebo-adjusted, and they fall short of Wall Streets 25% benchmark.
Mizuho Securities
―
Hold
―
Reiterated
11/26/24
Amgen's MariTide: Hold Rating Amid Efficacy and Safety Concerns in Obesity Treatment
Best Analysts Covering Amgen
Which Analyst Should I Follow If I Want to Buy AMGN and Sell After:
1 Month
xxx
Success Rate
15/29 ratings generated profit
Average Return
-0.50%
assigned a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 51.72% of your transactions generating a profit, with an average return of -0.50% per trade.
3 Months
xxx
Success Rate
20/34 ratings generated profit
Average Return
+4.12%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +4.12% per trade.
1 Year
Success Rate
31/51 ratings generated profit
Average Return
+5.71%
reiterated a buy rating 3 days ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 60.78% of your transactions generating a profit, with an average return of +5.71% per trade.
2 Years
xxx
Success Rate
37/52 ratings generated profit
Average Return
+15.80%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.15% of your transactions generating a profit, with an average return of +15.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AMGN Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
0
0
0
0
0
Buy
21
27
40
43
38
Hold
12
18
27
34
26
Sell
1
2
2
1
1
Strong Sell
0
0
0
0
0
total
34
47
69
78
65
Each month's total comprises the sum of three months' worth of ratings.
AMGN Financial Forecast
AMGN Stock Forecast FAQ
What is AMGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Amgen’s 12-month average price target is $333.78.
What is AMGN’s upside potential, based on the analysts’ average price target?
Amgen has 26.73% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AMGN a Buy, Sell or Hold?
Amgen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 10 hold ratings and 2 sell ratings.
What is Amgen’s price target?
The average price target for Amgen is $333.78. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $405.00 ,the lowest forecast is $215.00. The average price target represents 26.73% Increase from the current price of $263.38.
The highest analyst price target is $405.00 ,the lowest forecast is $215.00. The average price target represents 26.73% Increase from the current price of $263.38.
What do analysts say about Amgen?
Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.
How can I buy shares of AMGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.